Previous 10 | Next 10 |
Subsequent to FDA feedback, MediciNova (NASDAQ: MNOV ) has finalized the protocol for a Phase 3 clinical trial evaluating MN-166 (ibudilast) in patients with secondary progressive multiple sclerosis (MS) without relapses. More news on: MediciNova, Inc., Healthcare stocks news, Read m...
LA JOLLA, Calif., July 11, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced its plans for a Phase 3 clinical trial of MN-166 (ibudila...
Market Assessment MediciNova ( MNOV ) is a small-cap ($401M), clinical-stage biopharma with a diverse clinical program. Its primary focus is the clinical development of the lead investigative drug candidate, MN-166 , currently in early-mid-phase clinical trials for several neurological ...
LA JOLLA, Calif., June 12, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Geoffrey O'Brien, JD/MBA, Vice President and Executi...
LA JOLLA, Calif., June 05, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a kick-off meeting for the Phase 2b/3 clinical tria...
Gainers: Can-Fite BioPharma (NYSEMKT: CANF ) +38% . Outlook Therapeutics (NASDAQ: OTLK ) +30% . Del Frisco's Restaurant Group (NASDAQ: DFRG ) +27% . Orion Energy Systems (NASDAQ: OESX ) +23% . Sprint Corporation (NYSE: S ) +22% . ENDRA Life Sciences (NASDAQ: NDRA ) +18% . Sesen...
LA JOLLA, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Geoffrey O'Brien, JD/MBA, Vice President and Executiv...
LA JOLLA, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced its participation at the Kick-off Meeting for the Phase 3 ...
New data from a Phase 2/3 clinical trial, FIREFISH , evaluating Roche ( OTCQX:RHHBY ) unit Genentech's risdiplam in infants with spinal muscular atrophy Type 1 (SMA1) showed a treatment effect. The results were presented at the American Academy of Neurology Annual Meeting in Philadelphia...
Noteworthy events during the latter part of the week of April 28 - May 4 for healthcare investors. More news on: UroGen Pharma Ltd., ESSA Pharma Inc., EyePoint Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Company to rededicate efforts toward updating stakeholders on corporate vision, strategy, and ongoing activities LA JOLLA, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market o...
LA JOLLA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S....
LA JOLLA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s collaborator, Gilbert Youssef, M.D....